This issue of Rheumatic Disease Clinics, guest edited by Drs. Andrew Bomback and Meghan Sise, will cover several key aspects of Renal Involvement in Rheumatic Diseases. The Consulting Editor for the series is Dr. Michael Weisman. The topics discussed in the issue will include: ANCA, Lupus GN, proliferative and non-proliferative, Renal manifestations of RA, Secondary amyloidosis, Nephrotoxicity of select rheumatology drugs, Acute and chronic TI nephritis, rheumatology etiologies, TMAs with rheum etiologies, Anti-GBM, Autoimmune manifestations of viral infections, and Renal manifestations of IBD, among others.

This issue of Rheumatic Disease Clinics, guest edited by Dr. Candace Feldman, is Part II of a two-part issue covering Health Disparities in Rheumatic Diseases. This issue is one of four selected each year by series Consulting Editor, Dr. Michael Weisman. Topics discussed in this issue include, but are not limited to: Disparities in Lupus Care and Outcomes among U.S. Medicaid Beneficiaries, Understanding Risk Factors for Poor Outcomes in a Multiethnic Longitudinal Cohort, Impact of Psychosocial Factors on RA and Lupus Health Disparities, Racial/ethnic and geographic disparities in knee and hip osteoarthritis, Racial/ethnic Disparities in Osteoarthritis Management, Challenges and Strategies to Achieve Equitable Rheumatologic Care Across the World, Strategies to Reduce Disparities, Understanding and Addressing the Provider Biases and the Lack of Diversity in Lupus Clinical Trials, Community-engaged Research: Lupus Conversations, Leveraging Telemedicine as an Approach to Address Rheumatic Disease Health Disparities, and Understanding the Role and Challenges of Patient Preferences in Disparities in Rheumatic Disease Care.

This issue of Rheumatic Disease Clinics, guest edited by Dr. John Davis, will discuss Cancer and Rheumatic Diseases. This issue is one of four selected each year by series Consulting Editor, Dr. Michael Weisman. Topics discussed in this issue include, but are not limited to: rheumatic drugs and malignancy potential, biologic drugs and cancer, methotrexate and cancer, managing rheumatoid arthritis with cancer, Sjogren’s Syndrome and cancer, lupus and cancer, scleroderma and cancer, cancer and spondylarthritis, and cancer immunotherapy.

Guest edited by Drs. Jonathan Kay and Sergio Schwartzman, this issue of Rheumatic Disease Clinics will cover Controversies in Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman of Cedars-Sinai. Articles explore several questions, including, but not limited to: Is triple therapy or methotrexate plus a biologic the initial treatment of choice for RA patients; Is hypo or hyper-uricemia a risk requiring treatment for cardiac morbidity and mortality; Are there benefits and risks to biosimilars from a patient perspective; Should platelet-rich plasma be used to treat osteoarthritis; Is there a role for stem cell therapy to treat cartilage defects in osteoarthritis; Should any rheumatology patient, today, be treated with bone marrow ablation and stem cell transplantation; Is there effective prevention, prophylaxis, or treatment for CPPD arthritis; Is fibromyalgia a psychiatric disease or a pain syndrome; Should cyclophosphamide still be used to treat ANCA-associated vasculitis; Does methotrexate have a place in the treatment of psoriatic arthritis; Should hydroxychloroquine dosing be limited because of potential ocular toxicity; and Should generalized immunosuppression or targeted organ treatment be the best principle for overall management of SLE.

This issue of Rheumatic Disease Clinics, edited by Drs. John Imboden and Sarah Goglin, will cover a variety of important aspects of the neurological manifestations of rheumatic diseases. Topics discussed in the issue will include: Primary vasculitis of the central nervous system; Neurologic manifestations of primary Sjogren Syndrome; Neurologic manifestations of antiphospholipid antibody syndrome; Neurologic manifestations of rheumatoid arthritis and ankylosing spondylitis; Neuromyelitis optica; Neurosarcoid; Central nervous system infections associated with immunosuppressive therapy; and Neurologic manifestations of IgG4-related disease, among others.

In this issue of Rheumatic Disease Clinics, Guest Editors Laura E. Schanberg? MD and Yukiko Kimura? MD brings his considerable expertise to the topic of pediatric rheumatology. Top experts in the field cover key topics such as CARRA, Mental health, Social media and JIA, CV disease in PRD, and more. Provides in-depth, clinical reviews on pediatric rheumatology, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field; Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews. Contains 20 relevant, practice-oriented topics, such as Pharmacosurveillance of biologics in pediatric rheumatic disease (or JIA); cSLE in developing countries: impact of access to care, ethnic differences?; Biomarkers and Outcome Measures in cSLE; Role of environment on PRD; and more.

RISK OF CANCER IN RHEUMATIC DISEASES: IS THERE A ROLE OF THE UNDERLYING DISEASE?